Sernova Biotherapeutics Inc · TSX:SVA
Sernova Biotherapeutics — Sernova — BIOInvestor Forum 2020
26 slides from Sernova Biotherapeutics's conference presentation, October 2020

Slide 1: The Path To A Regenerative Medicine Cure
SEOVF TRADED ON The Path To A Regenerative Medicine Cure BIOInvestor Forum October 13 – 15 , 2020 th th

Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of applicable Canadian securities laws. Forward- looking statements in this presentation are statements that are not historical facts and are generally, but not always, identified by the words “expect

Slide 3: Sernova: Innovator & Leader
Sernova: Innovator & Leader Publicly traded, clinical-stage RM therapeutics solution innovator & leader: Cell therapy therapeutics solution platform treating chronic diseases & enhancing daily QOL Integrated RM therapeutic solution (Cell Pouch™ + therapeutic cells or tissue + immune-protection)

Slide 4: Sernova's Platform Approach
Sernova’s Platform Approach Integrated RM Therapeutic Solution for 28% 40% Treatment of Chronic Diseases 32% Cell Pouch Therapeutic Cells Immune Protection Implantable proprietary medical Human cells (donor / stem) & Technologies to protect device that provides vascularized tissues that produce & re

Slide 5: Worldwide IP / Patent Portfolio
Worldwide IP / Patent Portfolio International patents & patent applications portfolio in multiple patent families with broad application & continued expansion: Composition & use of medical devices for delivery & cell transplantation Glucose responsive insulin secreting stem cell technologies L

Slide 6: Sernova Pipeline
Sernova Pipeline CELL POUCH PRE- DEVELOPMENT CANDIDATE CLINICAL PHASE I PHASE II PHASE III STAGE INDICATION HUMAN DONOR ISLETS, P H A S E I /I I I N I T I AT E D HYPOGLYCEMIA SYSTEMIC IMMUNE DEC 2018 UNAWARENESS PROTECTION T1D A N T I C I PAT E D 2 ND ALL INSULIN LOCALLY IMMUNE- A P P R O VA L F O R

Slide 7: Diabetes Market Opportunities
Diabetes Market Opportunities IP Status 2020 Potential Patient Population Potential Commercial Opportunity (before market access considerations) T1D Severe HU T1D Severe HU Device / Method T1D Severe HU All T1D T1D Severe HU All T1D with Human with Human Patent with iPSC with iPSC with iPSC with iPS

Slide 8: RM Diabetes Competitive Landscape
RM Diabetes Competitive Landscape Clinical Efficacy Data: Device Vascularization Local Immune Financial Metrics Therapeutic C-peptide Levels Islet Engraftment Protection Technology (USD Millions) Measured in Bloodstream Demonstrated in Humans Phase I/II initiated late 2018 in T1D Interim data demons

Slide 9: Therapeutic Cells
Therapeutic Cells Therapeutic Cell Options Human donor cells enable early safety / efficacy testing in the clinic for indications & patients with unmet needs & advanced disease (i.e. diabetes HU patients). Supply is limited; however, they enable Cell Pouch validation in preparation for stem cell t

Slide 10: Immune Protection
Immune Protection Transplanted therapeutic cells must be protected from a natural immune system attack response. While established systemic transplantation immuno-suppression (anti-rejection) drugs can be effective, local immune protection (LIP) is optimal. LIP alternatives present different opp

Slide 11: Immune Protection
Immune Protection Conformal Coating Technologies: • Sernova’s proprietary cellular conformal coating technology - developed and optimized with years of research • It consists of a thin biocompatible porous polymer hydrogel coating surrounding therapeutic cells (islets, stem cells) • Proven to allow

Slide 12: Strategic Development Approach
Strategic Development Approach Device Therapeutic Immune Sernova Integrated Cells Protection RM Therapeutic Solution Immuno Portfolio Human Suppression Drugs Cell Therapeutic Donor (systemic) Pouch Cells Sernova Stem Cell Cell Encapsulation Proprietary Derived Conformal Coating Cell Pouch (iPSC / EP

Slide 13: Diabetes… Hope for a Functional Cure
Diabetes… Hope for a Functional Cure The Reality: Diabetes is one of the most prevalent diseases & pervasive medical problems impacting society & everyday quality of life (QOL) today 463 million affected worldwide and nearly 10% of these individuals have T1D(1) T1D represents a potential commerc

Slide 14: Diabetes Clinical Progress Summary
Diabetes Clinical Progress Summary Completion of first-in-human proof-of-concept study for diabetic condition HU Clinical protocol & regulatory package development for US Ph I / II clinical trial for Pre 2018 diabetic HU condition (T1D Study) FDA IND clearance to commence T1D Study T1D Study

Slide 15: Diabetes First Clinical Indication: HU
Diabetes First Clinical Indication: HU Hypoglycemia Hypoglycemia unawareness unawareness (HU), the(HU), most the most critical critical unmet needunmet needaffects in diabetes, in diabetes, 15% of T1D affects patients 15% (~240K of T1Dinpatients patients (~240 K patients in the US alone) the US alon

Slide 16: US Ph I/II Study Design
US Ph I/II Study Design US Ph I/II Safety, Tolerability, Efficacy Study Study Design: Company-sponsored IND. Open-label, single-arm study. Human donor islets are transplanted into the Cell Pouch after implantation & stable anti-rejection medication activity has been established. Primary Objective: T

Slide 17: US Ph I/II Case Study Early Findings
US Ph I/II Case Study Early Findings US Ph I/II Safety, Tolerability, Efficacy Study Safety Findings (90 days post-transplant) Incidence & severity of adverse events associated with Cell Pouch were monitored: No incidences of AEs determined to be probable or highly probable to the Cell Pouch Cel

Slide 18: US Ph I/II Case Study Early Findings
US Ph I/II Case Study Early Findings US Ph I/II Safety, Tolerability, Efficacy Study First Patient Observed Data Presented by Clinical Investigator* Early Efficacy Findings Islet Transplant Status: Before 3 Mo. After 90-day post-transplant glucose tolerance test (i.e. patient given a high sugar drin

Slide 19: US Ph I/II Case Study Early Findings
US Ph I/II Case Study Early Findings Improvement in ALL CGM Parameters Blood Glucose Over Time (mg/dL) Baseline: More excursions seen pre-transplant Parameter Baseline Post-transplant High Glucose Value (mg/dL) 285 231 Low Glucose Value (mg/dL) 50 66* # Glucose Excursions 15 3 # High Excursions 7 2

Slide 20: US Ph I/II 90-Days Post Transplant
US Ph I/II 90-Days Post Transplant Achievement of Secondary Endpoint “Survival of endocrine tissue in the Cell Pouch™ (defined by positive staining of islets during histological analysis) [ Time Frame: 90±5 days post-transplant for sentinel Cell Pouch™ ]” Islets Independent Pathologist reported: a

Slide 21: Earlier First-in-Human Study
Earlier First-in-Human Study First-in-World Successful Proof-of-Concept Study Design T1D subjects with HU & a history of severe hypoglycemic episodes Open-label, single-arm Donor islet transplantation 2 – 24 weeks post Cell Pouch implantation Primary Endpoint: Safety post Cell Pouch implanta

Slide 22: Hemophilia A Program
Hemophilia A Program Estimated ~20 K patients across North America & EU Market ~$10 B orphan indication Benefits of Sernova’s Cell Pouch with factor VIII releasing cells: Patients receive regular infusions of missing Standard clotting factors (i.e. factor VIII) Reduce / eliminate factor of C

Slide 23: Thyroid Disease Program
Thyroid Disease Program Estimated 150,000 thyroidectomies performed annually in US ~$2.2 B market opportunity Market Benefits of Sernova’s Cell Pouch with Thyroid releasing cells: Patients require lifelong thyroid hormone Reduce / eliminate daily life replacement therapy Standard long thyroi

Slide 24: NEXT STEPS – Action Plan
NEXT STEPS – Action Plan Develop licensed/acquired local immune-protection technologies for Platform therapeutic cells Technology Advance local immune-protected diabetes stem cell technology in preparation for First-in-Man (FIM) study Expand existing strong worldwide multi-family patent portfo

Slide 25: Management Team
Management Team Dr. Philip Toleikis PRESIDENT & CEO 20+ years experience in biotech management & product development in pharmaceutical & combination products. Previous Angiotech VP R&D (achieved $2 B market cap; product revenue $200 M per year). David Swetlow CPA, CA Board of Directors CFO Fra

Slide 26: 700 Collip Circle, Suite 114 London, Ontario Canada
700 Collip Circle, Suite 114 London, Ontario Canada N6G 4X8 info@sernova.com www.sernova.com
Source: Internet Archive copy of sernova.com
More decks from Sernova Biotherapeutics Inc
Merger or Acquisition (2026)16 slides · 2026
Investor Presentation (February 2025)24 slides · February 2025
Investor Presentation (December 2024)31 slides · December 2024
Investor Presentation (September 2024)21 slides · Sep 12, 2024
Investor Presentation (March 2024)32 slides · March 2024
Sernova — Investor Presentation (September 2023)27 slides · September 2023